Skip to main content
GHRS
NASDAQ Life Sciences

GH Research's GH001 Shows Significant Efficacy and Tolerability in Phase 2b TRD Trial

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
9
Price
$15.84
Mkt Cap
$982.546M
52W Low
$7.98
52W High
$20.5
Market data snapshot near publication time

Summary

GH Research reported compelling Phase 2b clinical trial results for GH001 in treatment-resistant depression, showing significant improvements in depression, anxiety, and quality of life with a favorable safety profile.


Key Events

  • Positive Phase 2b Results

    GH001 achieved a significant -15.5 mean reduction in MADRS total score from baseline on Day 8 compared to placebo (P<0.0001) in patients with treatment-resistant depression.

  • High Remission Rates

    The trial reported a 57.5% remission rate (MADRS total score ≤10) on Day 8, increasing to 73.0% in Open-Label Extension completers at Month 6.

  • Improved Secondary Endpoints

    GH001 significantly improved global illness severity (CGI-S), anxiety symptoms (HAM-A), and quality of life (Q-LES-Q-SF) compared to placebo, with these benefits sustained over six months.

  • Favorable Safety Profile

    The drug was generally well tolerated, with most adverse events being mild or moderate. Importantly, no treatment-emergent adverse events of flashbacks, suicidal intent, or suicidal behavior were reported.


Analysis

The 6-K filing details highly positive results from GH Research's GH001-TRD-201 Phase 2b clinical trial for treatment-resistant depression (TRD). The drug demonstrated significant reductions in depression severity, anxiety symptoms, and improvements in quality of life compared to placebo, with effects maintained over six months. The high remission rates and favorable safety profile, including no reports of suicidal intent or flashbacks, are particularly noteworthy for a psychedelic-based therapy in a patient population with high unmet needs. These results strongly support the continued development of GH001 and could significantly impact the company's valuation and future prospects.

At the time of this filing, GHRS was trading at $15.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $982.5M. The 52-week trading range was $7.98 to $20.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GHRS - Latest Insights

GHRS
Jun 04, 2026, 8:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $21.12 info
Change: -$3.44 (-14%) info
Market Cap: $1.448B info
GHRS
May 21, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $22.35
Real-time Price: $21.12 info
Change: -$1.23 (-6%) info
Market Cap: $1.448B info
GHRS
May 14, 2026, 9:20 AM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $21.57
Real-time Price: $21.12 info
Change: -$0.4497 (-2%) info
Market Cap: $1.448B info
GHRS
May 14, 2026, 9:02 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $21.57
Real-time Price: $21.12 info
Change: -$0.4497 (-2%) info
Market Cap: $1.448B info
GHRS
May 14, 2026, 7:21 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $22.34
Real-time Price: $21.12 info
Change: -$1.22 (-5%) info
Market Cap: $1.448B info
GHRS
Apr 29, 2026, 8:26 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $19.50
Real-time Price: $21.12 info
Change: +$1.62 (+8%) info
Market Cap: $1.448B info
GHRS
Apr 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $19.71
Real-time Price: $21.12 info
Change: +$1.41 (+7%) info
Market Cap: $1.448B info
GHRS
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $21.01
Real-time Price: $21.12 info
Change: +$0.110 (+0.52%) info
Market Cap: $1.448B info
GHRS
Mar 25, 2026, 11:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.96
Real-time Price: $21.12 info
Change: +$7.16 (+51%) info
Market Cap: $1.448B info
GHRS
Mar 05, 2026, 7:08 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $15.69
Real-time Price: $21.12 info
Change: +$5.43 (+35%) info
Market Cap: $1.448B info